1. DOJ supports Trump’s ruling to strike down ACA, including biosimilar provisions — Purdue Pharma settles opioids lawsuits in Oklahoma — Bristol-Myers gets FTC request for more info on Celgene deal -- See more on our front page news

    Plus NEW BOARDS added recently
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

ACOR drops 25%

Discussion in 'Acorda Therapeutics' started by anonymous, Sep 10, 2018 at 7:52 PM.

Tags: Add Tags
  1. Habib

    Habib Guest

    Has anyone gotten hired in the last 6 months? Sounds like people are only leaving
  2. anonymous

    anonymous Guest

    Just the interns. According to their posts, they have fixed the whole place. Their writing is a bit choppy but we try to let it slide or they scream racism.
  3. anonymous

    anonymous Guest

    Make your own decision and check the launch trajectory of another inhaled rx approval... afreeza. It tanked even with a co-promote and better quality managed market team and eventually sank to under $1. Hope and hype is not a business strategy . Liquidate equity while u can before it drops to < $10
  4. anonymous

    anonymous Guest

    F YOU. Leadership on target with inhaled LD. So ok BUY ACOR now!!!.

    great CEO, great Team, great Pipeline!!!!
  5. anonymous

    anonymous Guest

    Leadership fumbled the lifecycle planning of a product that was already commercialized. With no contingency plan when it imploded. Now hinging next chapter on a hopeful approval then create a market. We had a product, market share and revenue.... all we have now is a dream and hype. I will make a prediction.... even if it gets approved I can guarantee 8k filings of insider selling will be at an all time high.... what message will that send.... will be in a dumping syndrome.
  6. anonymous

    anonymous Guest

    Change scares the weak and gives adrenaline to the strong. Do you smell the fear coming from the weakest link in the chain. Yes it stinks ! Cafepharma is where these weaklings gather to stew in their stink.

    Fortunately, Acorda is made of stronger stuff. My friends are enargized, challenged, motivatived, cheerful, and greatful for how our leaders have navigated the shifting sands of our industry.

    Stand tall and be proud. Our strong leaders will overcome any change.
  7. anonymous

    anonymous Guest

    Habib, you can try and reclassify failure and ineptitude all you want, however the facts remain the same. Management bungled LCM and the regulatory approach to a non essential product that will impact revenue.

    Change is indeed in the air, however it’s not the change you profess. Sooner or later, leadership will have to answer for their mistakes. The question is how many will they take down with them?

    There is no accelerated approval for inhaled LD (you are already past your PDUFA date).

    Keep up the lies, it only proves you have nothing to save this organization other than rhetoric and spin. Investors are watching closely.
  8. anonymous

    anonymous Guest

    The above post is preposterous and shall be noted as mostly "BS". Leadership welcomes constructive criticism as well as well-thought out recommendations. Throwing out false 'know it all' posts is yet another dangerous behavior; before you post please look in the mirror and consider the damage you might do to a great Company.

    We are on track for a healthy rebound and accelerated approvals, international sales and an aggressive marketing campaign will fix all. Leadership is running ACOR 24/7.
  9. anonymous

    anonymous Guest

    So in other words, it’s factual. Got it!
  10. anonymous

    anonymous Guest

    Ron, friendly advice here: time to put Andy (your banker, not the moron running BD) to work. ACOR is best in someone else's hands.
  11. anonymous

    anonymous Guest

    The private (non-business) associations of all Leadership should be of no concern to rank & file.
  12. anonymous

    anonymous Guest

    Let these believers digest the Koolaid....likely underperformers that could not get hired somewhere else and are clinging to hope. As the industry shrinks with downsizing and acquisition they will eventually find sales positions at Payless Shoes. Good luck to you.... btw do you have these in a size 12?